BRAVE news: another one bites the dust

Affiliations

Comment

Jessica McHugh. Nat Rev Rheumatol. 2023 May.

. 2023 May;19(5):255.

doi: 10.1038/s41584-023-00957-x.

No abstract available

Comment on

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, de la Torre I, Dörner T. Morand EF, et al. Lancet. 2023 Mar 25;401(10381):1001-1010. doi: 10.1016/S0140-6736(22)02607-1. Epub 2023 Feb 24. Lancet. 2023. PMID: 36848918 Clinical Trial.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Petri M, Bruce IN, Dörner T, Tanaka Y, Morand EF, Kalunian KC, Cardiel MH, Silk ME, Dickson CL, Meszaros G, Zhang L, Jia B, Zhao Y, McVeigh CJ, Mosca M. Petri M, et al. Lancet. 2023 Mar 25;401(10381):1011-1019. doi: 10.1016/S0140-6736(22)02546-6. Epub 2023 Feb 24. Lancet. 2023. PMID: 36848919 Clinical Trial.

1. Morand, E. F. et al. Baricitinib for systemic lupus erythematosus: a double blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet https://doi.org/10.1016/S0140-6736(22)02607-1 (2023) - DOI - PubMed
1. Petri, M. et al. Baricitinib for systemic lupus erythematosus: a double blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet https://doi.org/10.1016/S0140-6736(22)02546-6 (2023) - DOI - PubMed